14.01.2020 Biofrontera AG  DE0006046113

DGAP-News: Biofrontera AG: Biofrontera announces 1-year follow-up results for its phase III study of photodynamic therapy for actinic keratosis on the extremities and trunk/neck


DGAP-News: Biofrontera AG / Key word(s): Study results/Miscellaneous
Biofrontera AG: Biofrontera announces 1-year follow-up results for its phase III study of photodynamic therapy for actinic keratosis on the extremities and trunk/neck

14.01.2020 / 06:30
The issuer is solely responsible for the content of this announcement.

Biofrontera announces 1-year follow-up results for its phase III study of photodynamic therapy for actinic keratosis on the extremities and trunk/neck

Leverkusen, Germany, January 14, 2020 - Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, today announced follow-up results for its Phase III clinical study evaluating the safety and efficacy of photodynamic therapy (PDT) with Ameluz(R) and the BF-RhodoLED(R) lamp for the treatment of actinic keratosis (AK) on the extremities, trunk and neck. After 12 months, the overall lesion recurrence rates were 14.1% after Ameluz(R) treatment, compared to 27.4% after placebo treatment in the Full Analysis Set (FAS; 11.7% vs. 24.6% in the Per Protocol Set, respectively).

"I am not aware of another pivotal clinical study showing similarly high clearance rates and low recurrence rates for the pharmaceutical treatment of actinic keratoses in the periphery," commented Biofrontera's CEO Prof. Hermann Luebbert. "With an overall lesion clearance rate of 77% one year after treatment, Ameluz(R) has once again demonstrated its unreached clinical efficacy."

The multi-center, randomized, double-blind, intra-individual study included 50 patients at six study sites in Germany, each with four to ten clinically confirmed AK lesions in comparable areas on the right and left side of the extremities and/or trunk/neck. Mild, moderate and severe actinic keratoses were treated with one or, if at least one lesion on each patient's side persisted after three months, two PDT applications. Each PDT consisted of the application of Ameluz(R) on one side of the patient, and an identically looking, feeling and smelling placebo gel on the other side. PDT illumination with 10 minutes of red light using the BF-RhodoLED(R) lamp followed after a 3-hour incubation with occlusion. The final examination of the patients took place three months after the last PDT. This clinical study phase was followed by a follow-up phase of up to one year after the last PDT, in which recurrence rates and numbers of new AKs and skin tumors were determined.

The results for the primary regulatory endpoint, demonstrating that Ameluz(R) was superior (p<0.0001) to placebo based on its mean total lesion clearance rate of 86% compared to 33% for placebo had been published in a Biofrontera press release on March 20, 2019.

The following table represents the treatment outcome after 3 months and the recurrence rates during one year after the last PDT (FAS).

Endpoints (all FAS) Ameluz(R)

Fully cleared lesions after 3 months

Fully cleared lesions after 3 months

12-month recurrence

12-month recurrence
Lesions per patients' side (overall) 86.0% 32.9% 14.1% 27.4%
Lesions per patients' side - extremities 83.5% 27.1% 16.2% 34.3%
Lesions per patients' side - neck/trunk 96.0% 55.5% 6.7% 10.7%
Mild lesions per patients' side (overall) 88.3% 37.3% 14.0% 39.2%
Moderate lesions per patients' side (overall) 84.3% 27.2% 11.6% 18.6%
Severe lesions per patients' side (overall) 71.4% 42.9% 20.0% 66.7%

Of the patients who were cleared of all AK lesions 3 months after treatment (67.3%), 62.5% overall and 60.9% of the patients treated on extremities (placebo 66.7% and 66.7%, respectively) remained fully cleared up to one year after the last PDT. No new AKs and only one basal cell carcinoma (BCC) skin tumor were identified in the treatment area after one year whereas outside the treatment area 6 AKs or skin tumors (BCC, squamous cell carcinoma) where identified.


Enquiries, please contact:

Biofrontera AG

Thomas Schaffer, Chief Financial Officer

+49 (0) 214 87 63 2 0
[email protected]
IR UK: Seton Services
Toni Vallen

+44(0) 20 7729 0805
IR and PR US: The Ruth Group
IR: Tram Bui
PR: Kirsten Thomas

+1 646-536-7035
+1 508-280-6592

About Biofrontera:

Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics.

The Germany-based company, with almost 200 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin. The company's lead product is the combination of Ameluz(R), a topical prescription drug, and medical device BF-RhodoLED(R) for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz(R) has been marketed in the EU since 2012 and in the United States since May 2016. In addition, the company markets the prescription medication Xepi(TM) for the treatment of impetigo in the United States. In the EU, the company also sells the dermocosmetics series Belixos(R), which offers specialized care for damaged or diseased skin.

Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by the current CEO Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on the US NASDAQ.www.biofrontera.com.

14.01.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language: English
Company: Biofrontera AG
Hemmelrather Weg 201
51377 Leverkusen
Phone: +49 (0)214 87632 0
Fax: +49 (0)214 87632 90
E-mail: [email protected]
Internet: www.biofrontera.com
ISIN: DE0006046113, NASDAQ: BFRA
WKN: 604611
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Munich, Stuttgart, Tradegate Exchange; Nasdaq
EQS News ID: 952723

End of News DGAP News Service

952723  14.01.2020 


Die wichtigsten Finanzdaten auf einen Blick
  2016 2017 2018 2019 2020 2021 2022
Umsatzerlöse1 6,13 12,03 21,11 31,26 30,35 28,79 25,74
EBITDA1,2 -10,95 -13,05 -17,72 -20,22 -4,70 27,95 1,87
EBITDA-Marge3 -178,63 -108,48 -83,94 -64,68 -15,49 97,08 7,26
EBIT1,4 -11,78 -13,93 -18,48 -23,38 -10,03 24,66 1,12
EBIT-Marge5 -192,17 -115,79 -87,54 -74,79 -33,05 85,66 4,35
Jahresüberschuss1 -10,58 -16,10 -9,58 -7,36 -13,02 33,86 -44,17
Netto-Marge6 -172,59 -133,83 -45,38 -23,54 -42,90 117,61 -171,60
Cashflow1,7 -10,74 -13,12 -13,43 -32,89 -2,85 30,44 -3,90
Ergebnis je Aktie8 -0,36 -0,43 -0,20 -0,16 -0,24 0,68 -0,77
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2022 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Baker Tilly

WKN Kurs in € Einschätzung Börsenwert in Mio. €
604611 0,946 60,36
KGV 2024e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
31,53 2,18 14,49 -3,88
2,97 - 2,35 32,28
Dividende '22 in € Dividende '23e in € Div.-Rendite '22e
in %
0,00 0,00 0,00 20.06.2023
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
31.05.2023 18.08.2022 - 27.04.2023
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-19,21% -31,35% -37,97% -20,50%
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Biofrontera AG  ISIN: DE0006046113 können Sie bei EQS abrufen

Biotechnologie , 604611 , B8F , XETR:B8F